Answers are grounded in this paper and cite their sources.
The cytokines BAFF and APRIL are clinically validated targets in multiple autoantibody-associated diseases. Their inhibition has shown promise in IgA nephropathy (IgAN), lupus nephritis (LN), and primary membranous nephropathy (pMN), with the potential to exert a disease-modifying effect. Povetacicept (ALPN-303) is an Fc fusion protein of a variant TACI domain engineered for more potent dual BAFF/APRIL inhibition than wild-type TACI or anti-BAFF or anti-APRIL antibodies. In healthy volunteers, povetacicept has been associated with on-target reductions in levels of immunoglobulin, including galactose-deficient IgA1 (Gd-IgA1), and antibody-secreting cells.
No takes yet. Share an insight, caveat, or question.
Tumlin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: